STOCK TITAN

EOM PHARMACEUTICAL HLDNGS - $IMUC STOCK NEWS

Welcome to our dedicated page for EOM PHARMACEUTICAL HLDNGS news (Ticker: $IMUC), a resource for investors and traders seeking the latest updates and insights on EOM PHARMACEUTICAL HLDNGS stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EOM PHARMACEUTICAL HLDNGS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EOM PHARMACEUTICAL HLDNGS's position in the market.

Rhea-AI Summary
EOM Pharmaceutical Holdings, Inc. announced an update on its clinical program for its lead drug candidate EOM613. The drug has shown promising results in a Phase 1/2a human clinical trial in COVID-19 patients, leading to plans to initiate a clinical program in Crohn's disease. The estimated global market for IBD therapies is expected to reach $27.0 billion annually by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
none
-
Rhea-AI Summary
EOM Pharmaceuticals announces positive results from its clinical trial of EOM613 in COVID-19 patients. The trial showed that EOM613 was well-tolerated and reduced pro-inflammatory cytokine levels in patients. The drug has potential utility in various chronic inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
clinical trial covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.65%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
none
EOM PHARMACEUTICAL HLDNGS

OTC:IMUC

IMUC Rankings

IMUC Stock Data

16.10M
5.70M
94.97%
3.96%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Westlake Village

About IMUC

immunocellular therapeutics, ltd. is a los angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. immunocellular has concluded a phase 2 trial of its lead product candidate, ict-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. immunocellular’s pipeline also includes: ict-121, a dendritic cell immunotherapy targeting the cd133 antigen on stem cells in recurrent glioblastoma; ict-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the stem-to-t-cell research program which engineers the patient’s hematopoietic stem cells to generate antigen-specific cancer-killing t-cells.